Retinal Toxicity of Anticancer Drugs: A Case Series

Introduction

According to the Swiss Cancer Report, in 2021, 26 000 men and 22 000 women were diagnosed with cancer, and these numbers are estimated to increase [1]. With the advent of molecularly targeted agents, significant advancements have been made in cancer treatment, transforming patient outcomes [2]. However, immunotherapies can introduce distinct ocular side effects, whose interest is rapidly growing in ophthalmology, as they need to be recognised because they can lead to permanent vision deterioration or can be potentially blinding [2].

The aim of this case series is to report known and unknown presentations of retinal toxicities associated with anticancer agents to help prompt identification by ophthalmologists.

Publikationsverlauf

Eingereicht: 28. Oktober 2024

Angenommen: 20. Januar 2025

Artikel online veröffentlicht:
27. Februar 2025

• References

• 1 Swiss Government. Swiss Cancer Report 2021: Rise in number of cancer patients coincides with decline in mortality. https://www.admin.ch/gov/en/start/documentation/media-releases.msg-id-85462.html Accessed: 22.01.2025
• 2 Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med 2022; 54: 1670
• 3 Nakao S, Ikeda Y, Emi Y. et al. Possibility of Müller cell dysfunction as the pathogenesis of paclitaxel maculopathy. Ophthalmic Surg Lasers Imaging Retina 2016; 47: 81-84
• 4 Malcolm J, Lune Wong CO, Ching J. et al. Paclitaxel may be a risk factor for retinal phototoxicity. Am J Ophthalmol Case Rep 2022; 25: 101292
• 5 Schorr C, Forindez J, Espinoza-Gutarra M. et al. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies. Int J Mol Sci 2023; 24: 8349
• 6 Omoti AE, Omoti CE. Ophthalmic manifestations of multiple myeloma. West Afr J Med 2007; 26: 265-268
• 7 Dong LF, Yao J, Wang XQ. et al. Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder. Biochem Biophys Res Commun 2015; 465: 678-684
• 8 Van Dijk EHC, Duits DEM, Versluis M. et al. Loss of MAPK Pathway Activation in Post-Mitotic Retinal Cells as Mechanism in MEK Inhibition-Related Retinopathy in Cancer Patients. Medicine (Baltimore) 2016; 95: e3457
• 9 Jiang Q, Cao C, Lu S. MEK/ERK pathway mediates UVB-induced AQP1 downregulation and water permeability impairment in human retinal pigment epithelial cells. Int J Mol Med 2009; 23: 771-777
• 10 Huang S, Guo Z, Wang M. et al. Ocular adverse events associated with BRAF and MEK inhibitor combination therapy: a pharmacovigilance disproportionality analysis of the FDA adverse event reporting system. Expert Opin Drug Saf 2023; 22: 175-181